Reuters logo
Diabetes drugmaker Novo Nordisk expects low to mid single-digit growth in 2018​
November 1, 2017 / 6:51 AM / 19 days ago

Diabetes drugmaker Novo Nordisk expects low to mid single-digit growth in 2018​

COPENHAGEN, Nov 1 (Reuters) - Denmark’s Novo Nordisk , the world’s top maker of diabetes drugs, posted third-quarter operating profit slightly above forecasts on Wednesday, and said it expected low to mid single-digit sales and operating profit growth next year.

The firm posted a quarterly operating profit of 12.04 billion Danish crowns ($1.88 billion) compared to an average 11.95 billion crowns forecast in a Reuters poll of analysts. .

The firm narrowed its 2017 sales growth forecast to 2-3 percent from 1-3 percent and lifted the higher range of its operating profit growth outlook to 3-6 percent from 1-5 percent, all measured in local currencies. ($1 = 6.3904 Danish crowns) (Reporting by Stine Jacobsen)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below